These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 17415050)

  • 1. Atazanavir in plasma-exchange treatment.
    Attema-de Jonge ME; Burger DM; Franssen EJ; Brinkman K
    AIDS; 2007 Apr; 21(7):884-5. PubMed ID: 17415050
    [No Abstract]   [Full Text] [Related]  

  • 2. Liquid chromatographic assay for the protease inhibitor atazanavir in plasma.
    Sparidans RW; Dost F; Crommentuyn KM; Huitema AD; Schellens JH; Beijnen JH
    Biomed Chromatogr; 2006 Jan; 20(1):72-6. PubMed ID: 15954163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.
    Ripamonti D; Cattaneo D; Maggiolo F; Airoldi M; Frigerio L; Bertuletti P; Ruggeri M; Suter F
    AIDS; 2007 Nov; 21(18):2409-15. PubMed ID: 18025877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
    Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
    HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic ritonavir-boosted atazanavir plasma concentration and concurrent omeprazole use.
    Goicoechea M; Best B; Capparelli E; Caperna J; Ballard C; Haubrich R
    AIDS; 2006 Oct; 20(16):2127-8. PubMed ID: 17053363
    [No Abstract]   [Full Text] [Related]  

  • 6. Revealing the metabolic sites of atazanavir in human by parallel administrations of D-atazanavir analogs.
    Cheng C; Vedananda S; Wu L; Harbeson S; Braman V; Tung R
    J Mass Spectrom; 2013 Sep; 48(9):1019-31. PubMed ID: 24078243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended mathematical model for "in vivo" quantification of the interaction betweeen atazanavir and bilirubin.
    Lozano R; Domeque N; Apesteguia AF
    J Clin Pharmacol; 2014 Feb; 54(2):161-7. PubMed ID: 24243081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir.
    Siccardi M; D'Avolio A; Baietto L; Gibbons S; Sciandra M; Colucci D; Bonora S; Khoo S; Back DJ; Di Perri G; Owen A
    Clin Infect Dis; 2008 Nov; 47(9):1222-5. PubMed ID: 18831695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
    J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
    Cleijsen RM; van de Ende ME; Kroon FP; Lunel FV; Koopmans PP; Gras L; de Wolf F; Burger DM
    J Antimicrob Chemother; 2007 Oct; 60(4):897-900. PubMed ID: 17704117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
    von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
    J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen.
    Colafigli M; Di Giambenedetto S; Bracciale L; Tamburrini E; Cauda R; De Luca A
    HIV Med; 2008 Mar; 9(3):172-9. PubMed ID: 18217998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.
    Klein CE; Chiu YL; Cai Y; Beck K; King KR; Causemaker SJ; Doan T; Esslinger HU; Podsadecki TJ; Hanna GJ
    J Clin Pharmacol; 2008 May; 48(5):553-62. PubMed ID: 18440920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
    Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urolithiasis in HIV-positive patients treated with atazanavir.
    Couzigou C; Daudon M; Meynard JL; Borsa-Lebas F; Higueret D; Escaut L; Zucman D; Liotier JY; Quencez JL; Asselah K; May T; Neau D; Vittecoq D
    Clin Infect Dis; 2007 Oct; 45(8):e105-8. PubMed ID: 17879904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case presentation: nephrolithiasis in a patient treated with atazanavir.
    Savini C; James C; Wilson S; Martin H; Szabo S; Scotto V
    J Assoc Nurses AIDS Care; 2008; 19(3):225-7. PubMed ID: 18457764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful management of a Jehovah's Witness with thrombotic thrombocytopenic purpura unwilling to be treated with therapeutic plasma exchange.
    Dabak V; Kuriakose P; Raman S
    J Clin Apher; 2007; 22(6):330-2. PubMed ID: 18080270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The experience of treating patients with thrombotic thrombocytopenic purpura with solvent detergent plasma.
    McCarthy LJ
    Br J Haematol; 2006 Apr; 133(1):107; author reply 108. PubMed ID: 16512839
    [No Abstract]   [Full Text] [Related]  

  • 20. Complications of plasma exchange in patients treated for thrombotic thrombocytopenic purpura. IV. An additional study of 43 consecutive patients, 2005 to 2008.
    Nguyen L; Terrell DR; Duvall D; Vesely SK; George JN
    Transfusion; 2009 Feb; 49(2):392-4. PubMed ID: 19389220
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.